Gilead Sciences (NASDAQ:GILD) executives on Tuesday outlined the company’s rationale for three recently announced transactions—its proposed acquisitions of Tubulis, Ouro Medicines, and Arcellx—framing the deals as additive to an already active late-stage pipeline and consistent with the company’s business development discipline. Management says pipeline momentum remains the priority Chairman and CEO Daniel O’Day said the […]